We are live on ! Find out more

Solid Biosciences

SLDB

Market cap $685M

6.39 USD

-0.09

1.39%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

6.27

-0.12

1.88%

1 day

-1.39%

5 days

4.41%

1 month

-10.75%

3 months

-20.52%

6 months

-9.36%

Year to date

17.25%

1 year

16.39%

5 years

-79.01%

10 years

-98.12%

About: Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Employees: 121

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 83.3%

Negative 0%

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia

- Obtaining Orphan designation from the European Commission reflects Solid's commitment to the global development of SGT-212 for individuals living with Friedreich's ataxia - - SGT-212 is a first-in-class dual route FA gene therapy designed to combine direct, MRI-guided delivery to the dentate nuclei with systemic delivery to reach cardiac and other systemic tissues - - Five participants have been dosed in the ongoing Phase 1b FALCON clinical trial and SGT-212 has been well tolerated as of October 5, 2026 - - Solid expects to report initial FALCON clinical data in Q1 2027 - CHARLESTOWN, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the European Commission (EC), acting upon the positive opinion of the European Medicines Agency's Committee for Orphan Medicinal Products, has granted Orphan designation to SGT-212 for the treatment of Friedreich's ataxia (FA).

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that seven abstracts have been accepted for poster presentation at the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany.

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

Solid Biosciences is a speculative buy, leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. SLDB's investment thesis centers on building both biological and controlled functional evidence, not just microdystrophin expression, to address physician and regulatory concerns. Competitive positioning against Sarepta and Regenxbio hinges on achieving clinically meaningful differentiation in function, safety, and eligibility, with time pressure from advancing rivals.

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028, supporting high-cost Phase 3 SGT-003 trials and multiple pipeline programs without near-term dilution risk. SGT-003's Phase 1/2 data show strong microdystrophin expression and safety, while additional programs in Friedreich's ataxia and CPVT expand addressable markets.

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired employee.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Jefferies Global Healthcare Conference Bo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m.

Solid Biosciences to Participate at Upcoming Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™